EXHIBIT "WITN3094001/25"

This is the exhibit marked "WITN3094001/1" referred to in the witness statement of Debra Anne Pollard dated 7 May 2019

11

UKHCDO

United Kingdom Haemophilia Centre Doctors' Organisation

Rollout of recombinant products to adult haemophilia patients in England

Definitions of eligibility and calculation of funding allocations

This document summarises the criteria that decide which patients in England are eligible for inclusion in the recombinant rollout programme and the start date that this funding will apply from. The document describes the principles used for calculating the amount of funding for each patient and explains the advisability of PCTs engaging in risk sharing arrangements.

The eligibility criteria for patients in England to be included in the recombinant rollout programme are:

- Haemophilia A, B or congenital factor VII deficiency
- Not previously treated with recombinant products prior to the rollout programme
- Date of birth prior to 27/2/1982 ie not covered under the previous agreement announced by the then Secretary of State for Health, Mr. Dobson in 1998

Patient funding will be calculated based on usage of plasma derived concentrate in the base year (April 2002 – March 2003), as described below. Clearly, some patients with a funding allocation (plasma derived treatment recorded in snapshot period) may not need treatment during the rollout period. Conversely, some patients eligible in terms of diagnosis, age and inhibitor status but without an allocation (no plasma derived treatment in the snapshot period) may need treatment during the rollout period. It is therefore anticipated that PCTs will take part in **risk sharing.**

The rollout comprises 2 tranches starting 2003 and 2005 respectively.

Patients starting in 2003 and continuing in 2004 are:

- Haemophilia A or B
- Not previously treated with recombinant products prior to the rollout programme
- Date of birth between 2/4/1962 and 26/2/1982 (end dates included)
- No inhibitor present

All other eligible patients will start in April 2005.

Calculation of allocations

Calculation of funding allocations is based on the difference in cost between plasma derived and recombinant therapy, including VAT on the whole cost of recombinant therapy.

A funding allocation is calculated on a patient by patient basis for each patient registered on the rollout database according to the above criteria. The allocation for each patient is based on their usage of plasma derived product in the base year (April 2002 to March 2003), and will include an uplift each year to allow for anticipated increased usage.

September 2004

Dr. Sybil Hirsch
Project Manager
National Haemophilia Database

and

Professor Frank Hill
Chairman
UKHCDO

On behalf of:
The Department of Health Forward Planning and Monitoring Group: Roll-out of Recombinant Treatment for Adult Haemophilia Patients